ArticleIBRO neuroscience reports2026
DNA methylation-estimated phenotypes, telomere length, aging and risk of intracranial aneurysms: Evidence from genetic studies.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk of intracranial aneurysm (IA) is increased in older population, suggesting a role for aging. To evaluate the association of genetic variants linked to DNA methylation-estimated phenotypes, telomere length, and aging, with the risk of IA by employing two-sample Mendelian randomization. Methods: Sex-specific summary-level outcome data were extracted from the GWAS of IA, including 23 cohorts with a total of 5140 cases and 71934 controls. All the study participants were of European ancestry. To improve validity, five varying Mendelian randomization techniques were used in the analysis (MR-Egger, weighted median, inverse variance weighted, simple mode, and weighted mode). Results: There was a suggestive negative causal relationship between Intrinsic epigenetic age acceleration and unruptured IA (P = 0.022, OR=0.906 [95% CI, 0.83-0.99]), though this did not remain significant after multiple testing correction (corrected P threshold=0.00208). No causal effect was observed between any other methylation-estimated phenotype and aSAH or UIA (all P > 0.05 after correction). A suggestive causal relationship between longevity and aSAH (P = 0.020, OR=1.100 [1.01-1.19]) was observed, with a 9.95% increase in disease risk per 1-SD increase in age, but this also did not withstand multiple testing correction. Each 1-SD increase in telomere length was associated with a 0.9% increase in DNA methylation-estimated granulocyte proportions (P = 0.0025, OR=1.009 [1.003-1.015]) and a 55% increase in intrinsic epigenetic age acceleration (P = 0.018, OR=1.552 [1.080-1.551]), with the former remaining significant after correction. Conclusion: A negative causal relationship between intrinsic epigenetic age acceleration and IA suggests that an increase in intrinsic apparent age acceleration reduces the risk of IA. The underlying mechanisms and their potential to lower the prevalence of IA as an intervention target require further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.